Results 71 to 80 of about 2,228 (187)
Ritlecitinib induced rapid clinical improvement in moderate‐to‐severe alopecia areata in real‐world practice. Early change in SALT at Week 12 strongly discriminated Week‐24 responders, supporting a pragmatic treat‐to‐target checkpoint, alongside improvements in clinician‐reported and patient‐reported outcomes and a favorable safety profile.
Giuseppe Gallo +4 more
wiley +1 more source
A Case of Hypogonadism Presented with Alopecia Universalis
et al. The effects of gonadotropin treatment on the immu- nological features of male patients with idiopathic hypogo- nadotropic hypogonadism. J Clin Endocrinol Metab 2000;85: 66-70. [CrossRef]
CELBEK, Gökhan +3 more
openaire +5 more sources
This systematic review included 38 studies assessing substance‐related and behavioural addictions in patients with chronic inflammatory skin diseases. Nicotine and alcohol use were the most frequently reported addictive behaviours. Addictions were associated with increased disease severity, impaired treatment outcomes and greater psychosocial burden ...
Enya Müller +5 more
wiley +1 more source
Alopecia Universalis Causes Serious Personality Derangements: First Report of Negative Impact of a Medical Condition on Personality (279 Patients) [PDF]
ObjectiveTo evaluate the reason of major behavioral problems in alopecia universalis patients, we tried to examine by way of MCMI- III whether these signs are transient, developmental or ingrained.Methods279 patients with alopecia universalis were ...
K.K. Pirkalani, Z. Talaee Rad
core +1 more source
Objective: To evaluate the effectiveness and safety of oral tofacitinib in treating patients with different forms of alopecia. Method: The prospective, interventional, open-label study was conducted at the Department of Dermatology, Jinnah ...
Misbah Zari Qadir +5 more
doaj +1 more source
Family quality‐of‐life burden in chronic spontaneous urticaria: A multicentre study
Poor control of chronic spontaneous urticaria (CSU) significantly worsens family members' quality of life, especially in emotional, physical, and social domains. Higher disease severity was linked to increased caregiving burden and household expenditures, highlighting the need for family‐centred CSU care and support across diverse global populations ...
Beatrice Martinez Zugaib Abdalla +33 more
wiley +1 more source
ABSTRACT A 31‐year‐old man with severe, corticosteroid‐resistant alopecia areata presented with substantial scalp hair loss (Severity of Alopecia Tool [SALT] score: 60%) despite a 1‐year regimen of topical corticosteroids, 5% minoxidil, and oral prednisolone. He was treated with allogeneic exosomes derived from adipose tissue mesenchymal stromal cells (
Masoumeh Kianpisheh +4 more
wiley +1 more source
S3‐Leitlinie Diagnostik und Therapie der Alopecia areata – Teil 1: Diagnostik und Epidemiologie
Zusammenfassung In dem vom Innovationsausschuss beim gemeinsamen Bundesausschuss (G‐BA) geförderten Projekt wurde von 2023 bis 2025 die S3‐Leitlinie zur Diagnostik und Therapie der Alopecia areata (AA) entwickelt. Die interdisziplinäre Expertengruppe bestand aus Vertretern der Deutschen Dermatologischen Gesellschaft, insbesondere aus der AG ...
Ulrike Blume‐Peytavi +13 more
wiley +1 more source
S3 guideline diagnostics and therapy of alopecia areata – Part 1: Diagnostics and epidemiology
Summary In the project funded by the Innovation Committee at the G‐BA, the S3 guideline for the diagnosis and treatment of AA was developed between 2023 and 2025. The interdisciplinary expert panel consisted of representatives from the German Dermatological Society, in particular from the Pediatric Dermatology Working Group, the Professional ...
Ulrike Blume‐Peytavi +13 more
wiley +1 more source
Evidence Based Treatment of Alopecia Areata
Background: Alopecia areata is a chronic autoimmune disease, involving non-scarring hair loss, which affects hair follicles and sometimes nails. Hair loss pattern presents as patchy alopecia, ophiasis, ophiasis inversa (sisapho), reticularis or diffuse ...
Eva Hariani, Nelva K. Jusuf
doaj +1 more source

